Sustanon

• Androgenic deficit after castration (in men)
• Eunuchoidism
• Hypopituitarism
• Hormonal impotence
• Male climax symptoms (decreased libido and physical and intellectual activity)
• Some forms of infertility with impaired spermatogenesis
• Osteoporosis caused by androgen insufficiency
• High levels of estrogen (in women)
• Uterine myoma (in women)
• Endometriosis (in women)
• Breast cancer (in women)
• Osteoporosis (in women)

• Individual hypersensitivity to the drug
• Prostate and breast carcinoma
• Prostate hyperplasia with disorder symptoms of urination
• Nephrosis or the nephrotic phase of nephritis
• Edema, hypercalcemia
• Disturbances of liver function, diabetes
• Heart failure or coronary disease
• Myocardial infarction
• Atherosclerosis in elderly men
• Pregnancy, lactation

PRO-GEN Sustanon is administered by deep intramuscular injection. The dosage is determined individually depending on the indication and the patient's responsiveness. Typically, to adults is administered intramuscularly 1 ml once in 14 days; when a therapeutic effect is achieved, Sustanon is administered 1 ml intramuscular once in 28 days. In male sterility (azoospermia, oligospermia): 2 ml 1 time in 2 weeks. In breast cancer in women: 1-2 ml every 1-2 weeks during the treatment period. The drug is not administered intravenously!

Sustanon is composed of three esters of testosterone (propionate, phenylpropionate, isocaproate and decanoate). Testosterone is the primary androgen hormone synthesized and released by the testes. It is responsible for the growth and development of male sex organs and secondary sexual characteristic features (maturation of prostate, seminal vesicles, penis and scrotum), male hair distribution (face, groin, chest), development of laryngeal muscles and body fat distribution. Retains nitrogen, sodium, potassium and phosphorus, increases anabolism and decreases protein catabolism.